thymulin: the nine-amino-acid thymic hormone that requires zinc to function

What is thymulin

thymulin (Facteur Thymique Serique, FTS) is a nonapeptide — a chain of nine amino acids, sequence Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn — produced exclusively by the epithelial cells of the thymus gland.^[3] Its molecular weight is 858.8 Da. The defining structural feature: thymulin requires an equimolar zinc ion to achieve the three-dimensional conformation that makes it biologically active. Remove the zinc, and the peptide is inert.^[1]

In that sense, thymulin is a metallopeptide — a machine that needs a specific metal part to run. The zinc binds at a dissociation constant of approximately 5 × 10⁻⁷ M at pH 7.4; activity drops to zero below pH 6.0.^[1] This zinc-dependency is not incidental: it is the mechanism by which the body’s zinc status directly gates thymic immune output.

From birth, thymulin circulates in serum and acts on T-cell precursors in the thymus, driving expression of surface differentiation markers CD2, CD3, CD4, and CD8 — the molecular nameplate system by which T-lymphocytes are classified into helper and cytotoxic lineages.^[3] Beyond the thymus, thymulin functions as a hypophysiotropic signal, stimulating ACTH, LH, and other pituitary hormones through cyclic AMP and cyclic GMP second-messenger pathways.^[11]

Serum thymulin titres follow a predictable lifespan trajectory: peak in children aged 5–10 years (mean titre 4.77), progressive decline from adolescence, nadir at age 36 (mean titre 0.66), stable through the oldest subjects tested at age 80 (mean 0.55 ± 0.16).^[2] This decline is partially a zinc-sufficiency problem: in aged mice, the primary defect is reduced zinc saturation of the peptide rather than absent synthesis, and zinc addition to thymic cultures from 24-month-old animals fully restores zinc-bound thymulin levels.^[5]

Thymulin Research: Studied Benefits and Biological Roles

The thymulin research record documents effects across four domains: immune maturation, inflammation control, analgesic activity, and — in preclinical models — neuroendocrine regulation.

T-cell maturation and NK cell activity. Thymulin is the primary thymic signal for T-lymphocyte differentiation, inducing CD2, CD3, CD4, and CD8 surface markers on thymocyte precursors.^[3] In chickens infected with infectious bronchitis virus, thymulin treatment at 10 ng/100g body weight enhanced natural killer cell cytotoxicity in a dose-dependent manner at 10 days post-infection, measured by ⁵¹Cr-release assay.^[10] The same model found that high-dose thymulin (50 ng/100g) paradoxically depressed NK activity relative to low dose — a bidirectional response that appears in several immune-modulation studies and underscores the precision required in immune research protocols.^[10]

Cytokine suppression and anti-inflammatory activity. At 15 μg/100g body weight intraperitoneally, thymulin prevented accumulation of IL-1β, IL-2, IL-6, TNF-α, and IFN-γ in LPS-treated mice and suppressed the LPS-induced Hsp70 peak in immune cells.^[9] In a relapsing-remitting EAE mouse model, PBCA nanoparticle-encapsulated thymulin at 1.5 mg/kg every other day for 25 days achieved complete disease restoration in treated animals while untreated controls had none, suppressing IFN-γ and IL-17A and inhibiting NF-κB phosphorylation at Ser276 and Ser536.^[13]

Analgesic and neuroinflammatory effects. A peptide analogue of thymulin (PAT) reduced mechanical and thermal hyperalgesia induced by endotoxin in rats at doses of 25 μg intraperitoneally — effects comparable to dexamethasone and indomethacin — and suppressed IL-1β, IL-6, TNF-α, and NGF in localized inflammatory models.^[6] In neuropathic pain models (chronic constriction injury and spared nerve injury), daily PAT treatment progressively attenuated mechanical allodynia and heat hyperalgesia.^[7]

Neuroendocrine signaling. Thymulin-Zn²⁺ stimulated ACTH release from rat anterior pituitary cells in vitro at maximum effect at 10 pM, with smaller increases in LH, elevated cyclic AMP and GMP, and inhibited prolactin — establishing thymulin as a bidirectional immune-neuroendocrine messenger.^[11]

Thymulin Peptide Benefits in Preclinical Models

Across the indexed studies, four categories of thymulin peptide benefit appear in preclinical models:

1. Immune reconstitution. In zinc-deficient human subjects, oral zinc repletion restored active thymulin, corrected T4⁺/T8⁺ ratios, and normalized IL-2 activity — establishing thymulin activity as a biomarker of zinc status.^[4] The thymulin and T-cell differentiation pathway underpins the reconstitution effect.
2. Cytokine balance modulation. Thymulin suppresses the pro-inflammatory cytokine cascade — IL-1β, IL-6, TNF-α, IFN-γ — via NF-κB and MAPK/p38 pathway inhibition, validated across mouse LPS models and the murine EAE autoimmune model.^[9][13]
3. Analgesic effects. PAT (a thymulin analogue) demonstrated pain-threshold restoration comparable to NSAID comparators at 25 μg intraplantar dosing in rodent inflammatory and neuropathic pain models.^[6][7][8]
4. Hair follicle activity (topical Zn-thymulin). In a pilot open-label human study (n=18, androgenetic alopecia, Norwood 2–7), topical zinc-thymulin spray was associated with a 32% mean increase in vellus-type hairs and a 23% increase in intermediate-type hairs over 4–10 months, with no adverse systemic effects.^[17] The study is limited by small n and open-label design; it is the only published human efficacy signal for zinc-thymulin.

For thymulin dosage in preclinical research, see the dedicated dosage reference page. For thymulin peptide mechanism of action, see the research section. Frequently asked questions about thymulin are indexed on the FAQ page.

What is thymulin?

A nine-amino-acid (nonapeptide) hormone secreted by thymic epithelial cells, thymulin acts as a circulating immune signal — particularly for T-lymphocyte maturation and cytokine regulation. Its full name is Facteur Thymique Serique (FTS); it is also called Zn-FTS in its zinc-bound bioactive form. Molecular weight: 858.8 Da. Sequence: Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn.^[1][3]

What is thymulin peptide used for?

In published research, thymulin is studied for its roles in T-lymphocyte maturation, immune modulation, anti-inflammatory cytokine balance, analgesic effects, and — in preclinical models — neuroprotection and wound healing. It is not approved for human therapeutic use in any jurisdiction. All dosing context in this reference is drawn from preclinical and ex-vivo studies.^{[3][6][7][9][13]}

What is the drug thymulin?

thymulin is not a drug — it is an endogenous nonapeptide hormone produced by the thymus and a research compound with no regulatory approval. In the peer-reviewed literature it is studied as a zinc-dependent thymic hormone involved in T-cell differentiation. Its synthetic form (metFTS and analogues) has been used in gene therapy and nanoparticle delivery research. No Phase 2 or Phase 3 clinical trials of synthetic thymulin are registered on ClinicalTrials.gov.^[18][13]

Thymulin peptide benefits in the literature

Studies in rodent and ex-vivo models report benefits in immune reconstitution, reduction of pro-inflammatory cytokines, analgesic effects, and possible neuroprotection. The 2019 EAE nanoparticle study showed complete disease restoration in treated animals.^[13] The 2017 pilot hair study showed a 32% vellus hair increase in androgenetic alopecia subjects.^[17] The strongest and most replicated findings are in cytokine suppression and T-cell maturation across multiple species.^{[3][4][5][9][10]}